| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 16, 2024 |
| Accession Number: | 0001104659-24-012890 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 16, 2024 |
| Accession Number: | 0001104659-24-012890 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
RADNOR, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced that, after the Company's shareholders adopted amendments to the articles of incorporation at the Special Meeting of Shareholders held on December 15, 2023 (the "Special Meeting") to effect a reverse stock split, to be followed immediately by a forward stock split, at a ratio of (i) not less than 1-for-50 and not greater than 1-for-100, in the case of the reverse stock split, and (ii) not less than 50-for-1 and not greater than 100-for-1, in the case of the forward stock split (collectively referred to as "stock splits"), the Company's Board of Directors (t
RADNOR, Pa., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced that on December 7, 2023, its Board of Directors (the "Board") declared a special cash dividend of $0.35 per share, payable on December 28, 2023 to shareholders of record as of the close of business on December 19, 2023 (the "Record Date"). The dividend is contingent on the adoption of amendments to the Company's articles of incorporation effecting the reverse stock split and the forward stock split of the Company's common stock at the Special Meeting of Shareholders to be held on December 15, 2023, and the Board thereafter giving effect to the Company's
RADNOR, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced financial results for the three and nine months ended September 30, 2023. THIRD QUARTER 2023 HIGHLIGHTS Financial Results Cash, cash equivalents and restricted cash totaled $15.7 million at September 30, 2023.The carrying value of the Company's ownership interests totaled $14.8 million at September 30, 2023. The total cost of the Company's ownership interests was $122.8 million.Net income for the three months ended September 30, 2023 was $0.9 million, or $0.06 per basic and fully diluted share, as compared with a net loss of $3.2 million, or $0.19 per bas
SC 13G/A - SAFEGUARD SCIENTIFICS INC (0000086115) (Subject)
SC 13G/A - SAFEGUARD SCIENTIFICS INC (0000086115) (Subject)
SC 13G/A - SAFEGUARD SCIENTIFICS INC (0000086115) (Subject)
RADNOR, Pa., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") has announced today that it filed Form 25 with the Securities and Exchange Commission (the "SEC") to voluntarily delist its shares of common stock from trading on The Nasdaq Stock Market LLC ("Nasdaq") in connection with its previously announced plan to deregister its common stock under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to delist the Company's common stock from trading on Nasdaq (referred to as the "Transaction"). The Company expects that the delisting will occur ten days after the filing of Form 25 so that trading will be suspended
Radnor, Pa, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") has announced today that it notified The Nasdaq Stock Market LLC ("Nasdaq") that it intends to file Form 25 with the Securities and Exchange Commission (the "SEC") on February 2, 2024 to voluntarily delist its shares of common stock from trading on Nasdaq in connection with its previously announced plan to deregister its common stock under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Company expects that the delisting will occur ten days after the filing of Form 25, at which point, the Company intends to file a Form 15 with the SEC certifying
RADNOR, Pa., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced that, as authorized by its Board of Directors (the "Board"), the Company will file amendments to its articles of incorporation with the Pennsylvania Department of State to effectuate a reverse stock split at a ratio of 1-for-100, to be followed immediately by a forward stock split at a ratio of 100-for-1 (collectively referred to as "stock splits"), which are expected to become effective on or about January 12, 2024, and the Company's common stock is expected to begin trading on The Nasdaq Stock Market LLC ("Nasdaq") on a post-forward stock split basis upon
15-12G - SAFEGUARD SCIENTIFICS INC (0000086115) (Filer)
SC 13E3/A - SAFEGUARD SCIENTIFICS INC (0000086115) (Subject)
EFFECT - SAFEGUARD SCIENTIFICS INC (0000086115) (Filer)
Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") has announced today that it notified The Nasdaq Stock Market LLC ("Nasdaq") that it intends to file Form 25 with the Securities and Exchange Commission (the "SEC") on February 2, 2024 to voluntarily delist its shares of common stock from trading on Nasdaq in connection with its previously announced plan to deregister its common stock under the Securities Exchange Act of 1934, as amended (the "Exchange Act").The Company expects that the delisting will occur ten days after the filing of Form 25, at which point, the Company intends to file a Form 15 with the SEC certifying that it has less than 300 shareholders of record, w
4 - SAFEGUARD SCIENTIFICS INC (0000086115) (Issuer)
4 - SAFEGUARD SCIENTIFICS INC (0000086115) (Issuer)
4 - SAFEGUARD SCIENTIFICS INC (0000086115) (Issuer)
TheracosBio today announced the appointment of former US Congressman Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty, MBA, as its Chief Financial Officer. Congressman Greenwood is an established leader in life sciences across business and public policy, and Mr. McGroarty has served as a CFO of public and private life sciences and technology companies. Both newly appointed team members will help shape the commercial strategy for Brenzavvy™ (bexagliflozin), a recently FDA-approved treatment for type 2 diabetes. "Accomplished leaders, Jim and Jeff will be valuable members of our team at this critical time for TheracosBio," said Albert R. Collinson, Ph.D., Pres
RADNOR, Pa., Dec. 21, 2020 /PRNewswire/ -- Safeguard Scientifics, Inc. (NYSE:SFE) announced today that Eric C. Salzman has been appointed Chief Executive Officer, effective December 21, 2020. Since April 1, 2020, Mr. Salzman has served as the Company's Chief Restructuring Officer. As CEO, Mr. Salzman will continue to focus on the value maximization and monetization of Safeguard's interests in its portfolio companies as well as the management of Safeguard's operations. "Since joining Safeguard earlier this year, we have been impressed with Eric's progress towards executing on Safeguard's strategy to drive value creation from the portfolio and return capital to our shareholders," said Robe